Semax Glaucoma Cohort Readout

A 2026 prospective cohort followed 50 people, representing 64 eyes, through surgery for stage II or III primary open-angle glaucoma. The study compared a bundled physiotherapy program after surgery with a control regimen that used Semax nasal drops. A visual-field measure improved in the combined-program group, but retinal structure measures did not differ significantly^[1]. This was not a randomized test of Semax alone.

The study concerns glaucomatous optic neuropathy after nonpenetrating deep sclerectomy, an operation intended to lower pressure inside the eye. It does not establish that Semax treats glaucoma. The experimental program combined several procedures, while the comparator also received Semax. Readers looking for broader context can use the Semax evidence overview, which separates experimental findings from established care.

The cohort followed 64 operated eyes

Investigators enrolled 50 patients with 64 affected eyes and indications for glaucoma surgery. They measured corneal-compensated intraocular pressure before surgery and during follow-up. Functional testing included mean deviation, pattern standard deviation, and the visual field index. Optical coherence tomography supplied average retinal nerve fiber layer thickness and ganglion cell complex measurements^[2].

Mean deviation summarizes overall visual-field sensitivity in decibels. A value moving closer to zero generally indicates less field loss, although learning effects and test variability can influence repeated measurements. Retinal nerve fiber layer and ganglion cell complex thickness are structural measures, which can move differently from functional results over a six-month window.

Assessments occurred before surgery and at one month, then again at three and six months. One month after surgery, the study group began two weeks of adjunctive physiotherapy. The program included transcranial magnetic and electrical stimulation plus endonasal electrophoresis with 0.1% Semax. Heliox inhalation using a 21/79 gas mixture was another component. The control group received 0.1% Semax nasal drops twice daily for ten days^[1]. These are reported study procedures, not instructions for readers.

Visual-field mean deviation improved

One month after surgery, corneal-compensated intraocular pressure had fallen significantly, with p below 0.001, and the abstract reports no later increase. In the study group, mean deviation changed from -8.62 plus or minus 1.86 dB to -7.03 plus or minus 1.36 dB after surgery. Following the bundled physiotherapy, it improved further to -4.33 plus or minus 0.98 dB, with p below 0.0001. The authors report that this change persisted through six months^[2].

The control group's mean deviation returned to baseline by month three, according to the abstract^[1]. That comparison suggests a functional signal associated with the combined program. It does not isolate which part of the program produced the difference because magnetic and electrical stimulation, Semax electrophoresis, and heliox were delivered together. The control regimen's Semax route and schedule also differed from the study group's exposure.

Surgery itself had already lowered intraocular pressure before the adjunctive program started, so changes after that point occurred in people selected for surgery rather than in an untreated glaucoma population. The study evaluates rehabilitation around a surgical pathway, not a substitute for pressure-lowering treatment. Six months is a short horizon. That window can describe persistence within the study period, but it cannot show whether the visual-field difference lasts over the years that matter in a chronic disease.

Retinal structure did not show a difference

The visual field index, average retinal nerve fiber layer thickness, and ganglion cell complex measures showed no statistically significant differences^[2]. That result limits any claim that the program preserved or restored retinal structure during follow-up. A functional test can improve without measurable structural change, especially over a short interval, but this cohort cannot determine the explanation.

The abstract does not report a blinded assessment, random allocation, group sizes, attrition, or adverse events. It also counts more eyes than patients. When both eyes from one person contribute data, observations may be correlated rather than fully independent; the indexed abstract does not explain how the analysis handled that issue. These omissions do not erase the observed signal, but they narrow confidence in it.

The design cannot assign the effect to Semax

Semax attribution remains impossible here. Both groups received the peptide in different forms, while the study group received additional interventions at the same time. A difference between groups therefore cannot answer whether Semax helped, whether electrical or magnetic stimulation helped, whether heliox helped, or whether their combination mattered; the study also cannot compare Semax with no Semax exposure.

A cleaner efficacy test would prospectively randomize comparable patients, keep surgical care consistent, and change one intervention at a time. Masked outcome assessment would reduce expectation effects on visual-field testing. Prespecified handling of two-eye data and complete adverse-event reporting would make the result easier to interpret. Longer follow-up would be needed to test whether functional change corresponds to durable preservation of vision.

What patients can take from the study

The cohort offers an early signal for a multi-part rehabilitation program after glaucoma surgery. It does not support self-directed Semax use or home stimulation, including nasal electrophoresis. Glaucoma can cause irreversible vision loss. Care depends on pressure control with ophthalmic monitoring, and questions about rehabilitation after surgery belong with the treating ophthalmologist, who can interpret visual-field variability and structural scans in context.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.